Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03731221 · ClinicalTrials.gov registry record · Early Phase 1
Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine
A Early Phase 1 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 196
- Enrollment target
NCT03731221 is a Early Phase 1 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 196 participants.
The verdict
NCT03731221, a Early Phase 1 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 196 participants
- Enrollment target
Study Summary
Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-based randomization. Assignments will be based on computer-generated code. Clinicians will not be blinded to the intervention, but all outcomes will be assessed by research personnel who are blinded to the group assignment.
Interventions
- DRUG Bupi HCI and lipo bupi
- DRUG Bupi HCI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2024-09-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03731221
The ClinicalTrials.gov registry entry for NCT03731221 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupi HCI and lipo bupi is the first listed.
NCT03731221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03731221 about?
NCT03731221 is a clinical study titled "Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine". Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-bas...
What is the current status of trial NCT03731221?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 196 participants. The study started on 2018-11-01. Estimated completion is 2024-09-19.
What interventions are being tested in trial NCT03731221?
The interventions under investigation include: Bupi HCI and lipo bupi (DRUG), Bupi HCI (DRUG).
Who is sponsoring clinical trial NCT03731221?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.